Veeva ePRO simplifies the collection and exchange of patient-reported results in digital clinical trials
BARCELONA, Spain, October 19, 2022 /PRNewswire/ — Veeva systems (NYSE: VEEV) today announced the availability of Veeva ePRO, an advanced key in digital patient-centered trials. The app makes it easier for patients to complete assessments on a mobile device or web browser and enables real-time data access for sponsors and clinical research sites. As part of a connected platform for clinical trials, study teams can use ePRO to exchange high-quality data across the clinical ecosystem to improve transparency and collaboration.
According to the research sites, the main challenges in retaining patients are the time required to participate in a trial, repetitive requests for information and the time spent entering data.1 Veeva ePRO enhances the patient experience by providing a modern, user-friendly application for populating patient-reported outcomes (PRO).
The app also helps streamline trial activities for sponsors and research sites. Sponsors can configure studies using survey and instrument libraries, and push ePRO and schedule definitions to research sites. Research sites can then automatically assign activities, automatically receive updates, and track patient progress without the need for other systems or applications.
“Veeva ePRO is designed to meet the needs of patients, sites and sponsors, and is connected for end-to-end execution,” says Tim Davis, Vice President of Strategy, MyVeeva for Patients at Veeva. “We are committed to working in partnership with our customers to deliver modern digital applications that help the life sciences industry move towards patient-centric digital trials. »
Veeva ePRO is part of the continued Veeva Vault Clinic, the industry’s first cloud platform that unifies clinical data management and operations. The Vault Clinical Suite includes Vault EDC, Veeva RTSMVeeva ePRO, Veeva CBD, Vault eTMF, Vault CTMS, Login to the Veeva site, Vault Payments, Starting the Vault Study and Training in the study of the safe. To learn more about Veeva ePRO: veeva.com/eu/ePRO.
Further information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva has more than 1,000 customers, from the world’s largest pharmaceutical companies to emerging biotech companies. As a public benefit company, Veeva is committed to balancing the interests of all affected parties, including customers, employees, shareholders, and the industries it serves. For more information, visit the website veeva.com/eu.
Veeva forward-looking statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected benefits or benefits of using our products and services, including some of our new solutions and applications that are still under development or not not available. These statements are based on our current expectations. Actual results, availability and future events related to these and services could differ materially from those provided in this release and we undertake no obligation to update such statements. There are numerous risks that could adversely impact our results, including the risks and uncertainties disclosed in our Form 10-Q for the period ending Sunday, July 31, 2022, which you can find here (a summary of the risks that could impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you may access on sec.gov.
1 CSIS research report, Assessing the impact of eClinical technologies and industry initiatives on sites2019
Logo: https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
SOURCE Veeva Systems
